Global Antidiabetics Market

Antidiabetics Market by Products (Thiazolodinediones, Insulin, Biguanides, GLP-agonists, Sulphonylureas, SGLT-2, DPP-4 Inhibitors, Meglitinides, and Alpha-glucosidase Inhibitors) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2502
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 36
  • No. Of Pages: 184
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global antidiabetics market size is estimated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing worldwide incidences of diabetes and growing demand for oral hypoglycemic and insulin drug.

Global Antidiabetics Market summary

Antidiabetics, also known as oral hypoglycemic agents, refers to types of drugs primarily designed to use for the treatment of diabetic patients. As per the reports published by International Diabetes Federation, global diabetes prevalence is estimated to increase by 550 million by 2030, which is expected to have a high impact on the antidiabetics market growth in the coming years. The reports further stated, diabetes and obesity share an integral relationship and comprise of the biggest public health challenge of the 21st century. It was reported that almost 85% of patients diagnosed with diabetes are also diagnosed with obesity. Furthermore, unregulated and irregular dietary habits are causing diabetes. The global obesity incidences was 1.3 billion in adults and over 35 million in children under the age of five in 2010.

The development of high accurate therapies for diabetes have increased tremendously due to the rising demand for advanced treatment methods to meet the needs of the increasing diabetic population size globally. The COVID-19 pandemic outbreak has brought an unpredicted effect on several businesses across ventures and had adversely affected the market. Rising financial recovery help from governments and other organizations can be key reasons, which is expected to make the market stable in the coming years.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing number of diabetic patients and growing incidences of lifestyle-induced disorders such as obesity are expected to boost the market growth in the coming years.
  • Rising number of the global base of geriatric population along with high demand for oral hypoglycemic and insulin drug are projected to fuel the market in the coming years.
  • Increasing R&D initiatives focusing at developing new products and the presence of several strong pipeline portfolio are the key factors driving the market growth.
  • Increasing government expenditure and awareness campaigns globally are major factors to propel the growth of the market during the forecast period.
  • New products exhibiting higher efficacies and the potential commercialization of these products are expected to offer immense opportunities for the market expansion.

Scope of the Report                          

The report on the global antidiabetics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Antidiabetics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Thiazolodinediones, Insulin, Biguanides, GLP-agonists, Sulphonylureas, SGLT-2, DPP-4 Inhibitors, Meglitinides, and Alpha-glucosidase Inhibitors)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Sanofi S.A.; Takeda Pharmaceuticals Company Limited; Eli Lilly and Company; Oramed Pharmaceuticals; Boehringer Sohn AG & Ko. KG; Merck & Co. Inc.; Novo Nordisk; Bristol-Myers Squibb; Halozyme Therapeutics; and Pfizer Inc.

Market Segment Insights

Insulin segment is expected to grow at a rapid pace

Based on products, the global antidiabetics market is segregated into thiazolodinediones, insulin, biguanides, GLP-agonists, sulphonylureas, SGLT-2, DPP-4 inhibitors, meglitinides, and alpha-glucosidase inhibitors. The insulin segment accounted for a key share of the market in 2020 and is anticipated to expand at a rapid pace in the coming years owing to the introduction of new products and the potential future commercialization of products currently in the pipeline. However, the biguanides segment is projected to hold a major share during the forecast period due to R&D activities for the development of biguanides product array.

Global Antidiabetics Market products

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market during the projected period due to high market penetration of modern insulin products and ongoing extensive R&D programs in the region. The market of Asia Pacific, however, is anticipated to exhibit a high CAGR during the forecast period owing to improving healthcare expenditure levels and increasing patient disposable incomes of a large number of the population in the region.

Global Antidiabetics Market region

Segments

Segments Covered in the Report
The global antidiabetics market has been segmented on the basis of
Products

  • Thiazolodinediones
  • Insulin
  • Biguanides
  • GLP-agonists
  • Sulphonylureas
  • SGLT-2
  • DPP-4 Inhibitors
  • Meglitinides
  • Alpha-glucosidase Inhibitors

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Sanofi S.A.
  • Takeda Pharmaceuticals Company Limited
  • Eli Lilly and Company
  • Oramed Pharmaceuticals
  • Boehringer Sohn AG & Ko. KG
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer Inc.

 

Competitive Landscape

Key players competing in the global antidiabetics market are Sanofi S.A.; Takeda Pharmaceuticals Company Limited; Eli Lilly and Company; Oramed Pharmaceuticals; Boehringer Sohn AG & Ko. KG; Merck & Co. Inc.; Novo Nordisk; Bristol-Myers Squibb; Halozyme Therapeutics; and Pfizer Inc. The main market players are continuously engaged in various market development activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market position.

Global Antidiabetics Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antidiabetics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antidiabetics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antidiabetics Market - Supply Chain
  4.5. Global Antidiabetics Market Forecast
     4.5.1. Antidiabetics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antidiabetics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Antidiabetics Market Absolute $ Opportunity
5. Global Antidiabetics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Antidiabetics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Antidiabetics Demand Share Forecast, 2019-2026
6. North America Antidiabetics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Antidiabetics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Antidiabetics Demand Share Forecast, 2019-2026
7. Latin America Antidiabetics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Antidiabetics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Antidiabetics Demand Share Forecast, 2019-2026
8. Europe Antidiabetics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Antidiabetics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Antidiabetics Demand Share Forecast, 2019-2026
9. Asia Pacific Antidiabetics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Antidiabetics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Antidiabetics Demand Share Forecast, 2019-2026
10. Middle East & Africa Antidiabetics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Antidiabetics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Antidiabetics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Antidiabetics Market: Market Share Analysis
  11.2. Antidiabetics Distributors and Customers
  11.3. Antidiabetics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Sanofi S.A.
     11.4.2. Takeda Pharmaceuticals Company Limited
     11.4.3. Eli Lilly and Company
     11.4.4. Oramed Pharmaceuticals
     11.4.5. Boehringer Sohn AG & Ko. KG
     11.4.6. Merck & Co. Inc.
     11.4.7. Novo Nordisk

Segments Covered in the Report
The global antidiabetics market has been segmented on the basis of
Products

  • Thiazolodinediones
  • Insulin
  • Biguanides
  • GLP-agonists
  • Sulphonylureas
  • SGLT-2
  • DPP-4 Inhibitors
  • Meglitinides
  • Alpha-glucosidase Inhibitors

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Sanofi S.A.
  • Takeda Pharmaceuticals Company Limited
  • Eli Lilly and Company
  • Oramed Pharmaceuticals
  • Boehringer Sohn AG & Ko. KG
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer Inc.

 

Key players competing in the global antidiabetics market are Sanofi S.A.; Takeda Pharmaceuticals Company Limited; Eli Lilly and Company; Oramed Pharmaceuticals; Boehringer Sohn AG & Ko. KG; Merck & Co. Inc.; Novo Nordisk; Bristol-Myers Squibb; Halozyme Therapeutics; and Pfizer Inc. The main market players are continuously engaged in various market development activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market position.

Global Antidiabetics Market keyplayers

Buy Report